Related Experiment Video
Updated: Apr 24, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
Published on: May 17, 2019
Anti-CD38 therapy in immune thrombocytopenia (ITP)
Waleed Ghanima1,2, Yu Hou3
1Department of Haemato-Oncology and Research, Østfold Hospital, Grålum, Norway.
None:
Anti-CD38 monoclonal antibodies have demonstrated rapid responses in immune thrombocytopenia, with response rates across several agents ranging from moderate to high. However, the durability of these responses after treatment discontinuation appears to vary. The therapeutic effects of anti-CD38 antibodies likely extend beyond depletion of CD38+ plasma cells and may involve broader modulation of the immune system.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Venous Thrombosis III: Interprofessional Care

